Ocugen (NASDAQ:OCGN) Earns “Buy” Rating from Chardan Capital

Ocugen (NASDAQ:OCGN)‘s stock had its “buy” rating reissued by equities researchers at Chardan Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $7.00 price target on the stock. Chardan Capital’s price objective points to a potential upside of 258.06% from the stock’s current price.

A number of other research firms also recently weighed in on OCGN. Oppenheimer initiated coverage on Ocugen in a report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 target price for the company. Canaccord Genuity Group started coverage on shares of Ocugen in a research report on Tuesday, March 17th. They set a “buy” rating and a $12.00 price target on the stock. Wall Street Zen upgraded shares of Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Finally, HC Wainwright upped their price target on Ocugen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ocugen presently has an average rating of “Moderate Buy” and an average target price of $9.75.

Ocugen Stock Performance

Shares of OCGN stock traded up $0.04 during trading on Wednesday, reaching $1.96. 8,598,878 shares of the company’s stock were exchanged, compared to its average volume of 7,992,266. Ocugen has a twelve month low of $0.57 and a twelve month high of $2.73. The firm’s fifty day moving average price is $1.73 and its 200-day moving average price is $1.53. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 8.04. The stock has a market capitalization of $641.04 million, a PE ratio of -8.50 and a beta of 2.75.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). The firm had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.86 million. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. As a group, sell-side analysts anticipate that Ocugen will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its holdings in Ocugen by 76,831.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 82,317 shares of the company’s stock worth $111,000 after purchasing an additional 82,210 shares during the period. Virtu Financial LLC acquired a new position in shares of Ocugen during the fourth quarter valued at about $106,000. NewEdge Advisors LLC boosted its position in shares of Ocugen by 69.0% during the 4th quarter. NewEdge Advisors LLC now owns 135,460 shares of the company’s stock worth $183,000 after purchasing an additional 55,305 shares in the last quarter. Millennium Management LLC boosted its position in shares of Ocugen by 29.7% during the 4th quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock worth $7,285,000 after purchasing an additional 1,234,268 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Ocugen in the 4th quarter valued at about $196,000. 10.27% of the stock is owned by institutional investors.

Ocugen News Summary

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised its price target to $10 and initiated/maintained a “buy” stance, citing upside versus current levels — this upgrade increases buy-side visibility and likely supported today’s buying interest. Benzinga
• Positive Sentiment: Ocugen reported topline 12‑month Phase 2 ArMaDa results for OCU410 showing a statistically significant 31% reduction in GA lesion growth (optimal dose) vs. control, no treatment‑related serious adverse events, and plans for a Phase 3 start in Q3 2026 — this is the primary long‑term fundamental catalyst. Phase 2 Release
• Positive Sentiment: Index inclusion: Ocugen was added to the S&P Biotechnology Select Industry Index — increases institutional/ETF exposure and may boost demand from index‑tracking funds. Yahoo Finance
• Positive Sentiment: Wall Street attention/targets: several recent analyst targets cluster around $10–$12 (median ~$10), and media pieces highlight a healthy cash position — both support a constructive medium‑term view if trials proceed. Quiver / Analyst Notes
• Neutral Sentiment: Coverage highlighting Ocugen’s cash runway and recent R&D spend could be supportive but requires watching burn vs. upcoming Phase 3 costs. Yahoo – Cash Position
• Neutral Sentiment: Short‑interest data in public feeds appears inconsistent/erroneous (zero/NaN entries); treat those reports cautiously — no clear short squeeze signal.
• Negative Sentiment: Some outlets reported an immediate share decline after the trial update (market underperformance/pullback), suggesting investors digested the results with caution — reasons include the need for confirmatory Phase 3 data, regulatory risk, and profit‑taking after recent run‑up. Seeking Alpha

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.